Therapeutic potential for blockade of the CD40 ligand, gp39.
Buhlmann
J E
JE
Department of Microbiology, Dartmouth Medical School, Lebanon, New Hampshire 03756, USA.
Noelle
R J
RJ
D000818:Animals; D019138:Antibodies, Blocking / Q000627:therapeutic use*; D001168:Arthritis / Q000628:therapy; D019013:CD40 Antigens / Q000276:immunology*; D023201:CD40 Ligand; D006086:Graft vs Host Disease / Q000628:therapy; D006801:Humans; D007154:Immune System Diseases / Q000628:therapy*; D008180:Lupus Erythematosus, Systemic / Q000628:therapy; D008562:Membrane Glycoproteins / Q000037:antagonists & inhibitors / Q000276:immunology*; D009103:Multiple Sclerosis / Q000628:therapy
D019138:Antibodies, Blocking; D019013:CD40 Antigens; D008562:Membrane Glycoproteins; D023201:CD40 Ligand